Dr. Carlo Gambacorti-Passerini - CML - Chronic myeloid leukemia
''Carlo Gambacorti-Passerini (born 1957) is an Italian oncologistand hematologist known for his contributions to cancer research. He is presently Professor of Internal Medicine at the University of Milan Bicoccain Italy and Director of the Clinical Research Unit at S. Gerardo Hospital, Monza, Italy. Previously he was Senior Investigator and Head of the Oncogenic Fusion Proteins Unit at the National Cancer Institute, Milan Italy (1990-2003), Professor of Oncology and Hematology at McGill University, Montreal, Canada (2004-2007).
His main scientific contribution relates to the preclinical and clinical development of imatinib.''
Extract from http://en.wikipedia.org/wiki/Carlo_Gambacorti-Passerini
''I played a key role in the clinical testing of Imatinib, an inhibitor of Bcr/Abl, an OFP which causes chronic myeloid leukemia. This work represents the first example of rational drug design, where a drug is developed to block an early event in the molecular pathogenesis of a human cancer.''
Extract from http://www.mcgill.ca/translational-research-cancer/researcher-biographies/gambacorti-passerini/
VIDEOS IN ENGLISH
CML18 Are TKI really safe ?
November 18, 2018, ESH
Bosutinib Versus Imatinib (CML) Follow Up Study - Carlo Gambacorti-Passerini, MD
January 6, 2012, Oncology.TV
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
February 1, 2012, Chris Bubeck
VIDEOS IN ITALIAN
Pazienti LMC e Vaccini contro il Covid-19: Relatore Prof. Carlo Gambacorti Passerini
April 18, 2021, Aip Lmc
CML18 Are TKI really safe ?
November 18, 2018, ESH
Bosutinib Versus Imatinib (CML) Follow Up Study - Carlo Gambacorti-Passerini, MD
January 6, 2012, Oncology.TV
BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
February 1, 2012, Chris Bubeck
VIDEOS IN ITALIAN
Pazienti LMC e Vaccini contro il Covid-19: Relatore Prof. Carlo Gambacorti Passerini
April 18, 2021, Aip Lmc
ARTICLES
Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
2011, American Society of Clinical Oncology
2011, American Society of Clinical Oncology
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).